Tobramycin Sulfate Injection
Brand names: Tobramycin
Category: Anti-Infective
FDA status: To Be Discontinued · Last FDA update: Jul 17, 2026 · First posted: Jul 17, 2026 · 1 manufacturers, 1 listed presentations
As of Jul 17, 2026, the FDA lists Tobramycin Sulfate Injection as being discontinued. Of 1 manufacturer presentations, 1 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Tobramycin Sulfate, Injection, 80 mg/2 mL (40 mg/mL); 2 mL Multiple Dose Glass Fliptop Vial (NDC 0409-3578-01) NDC 0409-3578-01 |
Hospira, Inc., a Pfizer Company | Not specified | Discontinuation of the manufacture of the drug |
Related medications in shortage
Other Anti-Infective medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Tobramycin Sulfate Injection (FDA data as of Jul 17, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Tobramycin Sulfate Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/tobramycin-sulfate-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).